Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144351 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1 study, sponsored by Elan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01144351: Clinical Trial Phase 1 study, sponsored by Elan Pharmaceuticals.
NCT01144351 is a Phase 1 study that was terminated before completion, run by Elan Pharmaceuticals. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144351, a Phase 1 study, was terminated before completion, sponsored by Elan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
Interventions
- DRUG Placebo
- DRUG ELND002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-03 |
| Phase | Phase 1 |
Why NCT01144351 stopped before completion
NCT01144351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01144351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01144351 about?
NCT01144351 is a clinical study titled "A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis". The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
What is the current status of trial NCT01144351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2010-03.
What interventions are being tested in trial NCT01144351?
The interventions under investigation include: Placebo (DRUG), ELND002 (DRUG).
Who is sponsoring clinical trial NCT01144351?
This trial is sponsored by Elan Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01144351's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia